<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nuvation Bio Inc — News on 6ix</title>
    <link>https://6ix.com/company/nuvation-bio-inc</link>
    <description>Latest news and press releases for Nuvation Bio Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 22:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nuvation-bio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a41878dffbe2df10a806.webp</url>
      <title>Nuvation Bio Inc</title>
      <link>https://6ix.com/company/nuvation-bio-inc</link>
    </image>
    <item>
      <title>Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-ibtrozir-taletrectinib-showed-highly-durable-responses-in-longer-term-follow-up-data-from-pivotal-studies-presented-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-ibtrozir-taletrectinib-showed-highly-durable-responses-in-longer-term-follow-up-data-from-pivotal-studies-presented-at-aacr-2026</guid>
      <pubDate>Tue, 21 Apr 2026 22:00:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The updated efficacy and safety results for both TKI-naïve and TKI-pretreated patients were presented at the American Association for Ca</description>
    </item>
    <item>
      <title>Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-4-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-4-2026</guid>
      <pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026.</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-fourth-quarter-210500358</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-fourth-quarter-210500358</guid>
      <pubDate>Tue, 17 Feb 2026 21:05:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025.</description>
    </item>
    <item>
      <title>Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-pivotal-global-130000809</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-pivotal-global-130000809</guid>
      <pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, February 09, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing global SIGMA study (also known as G203; NCT05303519) of safusidenib that expands it to a Phase 3 trial. SIGMA is evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-preliminary-fourth-130000880</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-preliminary-fourth-130000880</guid>
      <pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, January 12, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI® (taletrectinib) and provided a 2026 outlook ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.</description>
    </item>
    <item>
      <title>Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-eisai-enter-exclusive-123000494</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-eisai-enter-exclusive-123000494</guid>
      <pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
      <description>NEW YORK &amp; TOKYO, January 12, 2026--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., &quot;Nuvation Bio&quot;), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agree</description>
    </item>
    <item>
      <title>Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-present-44th-annual-210500924</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-present-44th-annual-210500924</guid>
      <pubDate>Tue, 06 Jan 2026 21:05:00 GMT</pubDate>
      <description>NEW YORK, January 06, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, CA.</description>
    </item>
    <item>
      <title>Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-publication-positive-130000267</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-publication-positive-130000267</guid>
      <pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
      <description>NEW YORK, December 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology.</description>
    </item>
    <item>
      <title>Nuvation Bio to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-participate-upcoming-investor-210500996</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-participate-upcoming-investor-210500996</guid>
      <pubDate>Wed, 26 Nov 2025 21:05:00 GMT</pubDate>
      <description>NEW YORK, November 26, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences:</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-third-quarter-210500094</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-third-quarter-210500094</guid>
      <pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
      <description>NEW YORK, November 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000775</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000775</guid>
      <pubDate>Thu, 23 Oct 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, October 23, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 (NCT05303519), a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-grade IDH1-mutant astrocytoma following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Sa</description>
    </item>
    <item>
      <title>Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-third-quarter-200500395</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-third-quarter-200500395</guid>
      <pubDate>Mon, 20 Oct 2025 20:05:00 GMT</pubDate>
      <description>NEW YORK, October 20, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025.</description>
    </item>
    <item>
      <title>Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000346</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000346</guid>
      <pubDate>Tue, 30 Sep 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, September 30, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 study evaluating the efficacy and safety of IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of patients with resected ROS1-positive (ROS1+) early-stage non-small cell lung cancer (NSCLC).</description>
    </item>
    <item>
      <title>Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-receives-approval-japan-113000291</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-receives-approval-japan-113000291</guid>
      <pubDate>Fri, 19 Sep 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, September 19, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC). As part of an exclusive license agreement entered in 2023, Nippon Kayaku will commerci</description>
    </item>
    <item>
      <title>Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-data-pivotal-100000620</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-data-pivotal-100000620</guid>
      <pubDate>Sun, 07 Sep 2025 10:00:00 GMT</pubDate>
      <description>NEW YORK, September 07, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The new findings are being highlighted in an oral presentation and poster sessi</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-second-quarter-113000511</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-second-quarter-113000511</guid>
      <pubDate>Thu, 07 Aug 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, August 07, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-present-data-ibtrozi-120000978</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-present-data-ibtrozi-120000978</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK, August 05, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025 in Barcelona, Spain, and the European Society of Medical Oncology Congress Meeting (ESMO) October 17–21, 2025 in Berlin, Germany. These data include new results from the pivotal Phase 2 TRUST-I and TRUST-</description>
    </item>
    <item>
      <title>Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-second-quarter-200500071</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-second-quarter-200500071</guid>
      <pubDate>Thu, 24 Jul 2025 20:05:00 GMT</pubDate>
      <description>NEW YORK, July 24, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025.</description>
    </item>
    <item>
      <title>Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-national-comprehensive-110000116</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-national-comprehensive-110000116</guid>
      <pubDate>Tue, 24 Jun 2025 11:00:00 GMT</pubDate>
      <description>NEW YORK, June 24, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI™) has been added as a Preferred Agent in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Non-Small Cell Lung Cancers (NSCLC), updated on June 20. Specifically, the NCCN Guidelines® now include taletrectinib (IBTROZI) as a Preferred Ag</description>
    </item>
  </channel>
</rss>